NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/05/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization7.66 mln
Float1.45 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
41
/ 100
Slightly lagging
Debt / Equity
3.27
Highly leveraged
ROE
-214
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
CNS Pharmaceuticals is a Houston-based company founded in 2017, focused on finding new ways to treat cancerous brain tumors. Its two main experimental treatments, TPI 287 and Berubicin, are currently being tested in advanced human trials targeting some of the most aggressive forms of brain cancer. The company works alongside Cortice Biosciences under a formal licensing arrangement to advance its research goals.
